Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients

NCT05447013 is registered in ClinicalTrials.gov with George Papanicolaou Hospital as lead sponsor.

NCT NCT05447013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05447013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients
Lead sponsor
George Papanicolaou Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 2, 2021
Completion date
December 31, 2022
Enrollment
182 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

severe covid-19